Skip to main content

The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation

Summary

We have studied the pharmacokinetics of tulobuterol given transdermally or by aerosol inhalation in healthy male volunteers.

Tulobuterol was rapidly absorbed after inhalation, with a tmax of 0.8–1.5 h. The Cmax and the AUC increased linearly with dose.

Tulobuterol was well absorbed after transdermal administration, with an absorption lag-time of about 4 h. The Cmax and AUC increased linearly with dose and the tmax was about 9–12 h. The mean percentage of drug absorbed during the application of a patch for 24 h was 82–90% after a single dose and 82–85% during repeated dosing.

The mean urinary recoveries as unchanged drug after a single inhalation and patch application were 3–4% and 5–6% respectively.

Tulobuterol did not accumulate during repeated inhalation or transdermal application. It was well tolerated, except for an increase in heart rate of 10–20 beats · min−1 after five repeated applications of a 4 mg patch.

This is a preview of subscription content, access via your institution.

References

  1. Shita K, Kurihara N (1978) Double-blind trial of o-chloroalpha [(tert-burylamino)methyl]benzylalcohol hydrochloride (C-78) in patients with chronic obstructive pulmonary disease. Jap J Clin Med 55: 868–878

    Google Scholar 

  2. Maesen F, Smeets J, Polderman J (1983) A comparative study of bronchospasmolytic effect of tulobuterol and fenoterol in patients suffering from a reversible bronchial obstruction. Arzneimittelforschung (Drug Res) 12: 1696–1698

    Google Scholar 

  3. Patel KR (1984) Bronchodilator effect of inhaled tulobuterol. A new beta2 agonist in patients with asthma. Respiration 46 [Suppl 1]: 116

    Google Scholar 

  4. Patel KR (1985) Comparison of bronchodilator effect of tulobuterol and salbutamol aerosols in patients with asthma. Br J Clin Pharmacol 20: 717–718

    Google Scholar 

  5. Patel KR (1986) Bronchodilator activity of a new inhaled beta2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma. Br J Clin Pharmacol 21: 234–237

    Google Scholar 

  6. Patel KR (1990) Prolonged treatment with oral and inhaled tulobuterol does not induce airways tachyphylaxis. Lung 168 [Suppl]: 210–218

    Google Scholar 

  7. Sienra-Monge JJ, Graham-Zapata LF, Del Rio-Navarro BE (1990) Clinical evaluation of tulobuterol aerosol in childhood asthma. J Int Med Res 18: 483–488

    Google Scholar 

  8. Schaffler K, Reeh PW (1987) Induction and reduction of muscle tremor upon acute and repeated administration of the β2-agonists terbutaline, salbutamol and tulobuterol. Int J Clin Pharmacol Ther Toxicol 25: 673–682

    Google Scholar 

  9. Mitsuhashi M, Kimura T, Tateno K (1985) Therapeutic serum levels of tulobuterol hydrochloride in children with bronchial asthma (in Japanese). Prog Med 5: 1253–1257

    Google Scholar 

  10. Matsumura K, Kubo O, Tsukada T, Nishide K, Watanabe K, Hirobe M (1982) Determination of tulobuterol in human serum by electron-capture gas-liquid chromatography. J Chromatogr 230: 148–153

    Google Scholar 

  11. Matsumura K, Kubo O, Sakashita T, Kato H, Watanabe K, Hirobe M (1983) Determination of serum tulobuterol concentrations by mass fragmentography: comparison with an electroncapture gas chromatographic method. J Pharm Sci 72: 570–572

    Google Scholar 

  12. Statistical Consultants (1986) PCNONLIN and NONLIN84: software for the statistical analysis of nonlinear models. The American Statistician 40: 1

    Google Scholar 

  13. Bristow MR, Ginsberg R (1986) Beta-2 receptors on myocardial cells in human ventricular myocardium. Am J Cardiol 57: 3F-6F

    Google Scholar 

  14. Lipworth BJ, Irvine NA, McDevitt DG (1991) A dose-ranging study to evaluate the β1-adrenoceptor selectivity of bisoprolol. Eur J Clin Pharmacol 40: 135–139

    Google Scholar 

  15. Lipworth BJ, McDevitt DG (1992) Inhaled β2-adrenoceptor agonists in asthma: help or hindrance? Br J Clin Pharmacol 33: 129–138

    Google Scholar 

  16. Kubo S, Kase Y, Miyata T, Kito G, Uesaka I (1975) Pharmacological studies of 1-(o-chloro-phenyl)-2-tert-butyl-aminoethanol (C-78), a new bronchodilator. Arzneimittelforschung (Drug Res) 25: 1028–1037

    Google Scholar 

  17. Kubo S, Uesaka I, Matsubara I, Ishihara T, Kase Y (1977) Pharmacological studies of o-chloro-α-[(tert- butylamino) methyl]-benzylalcohol hydrochloride (C-78), a new bronchodilator II, actions on the cardio-vascular system and smooth muscle organs. Arzneimittelforschung (Drug Res) 27: 1433–1439

    Google Scholar 

  18. Terpstra GK, Raaijmakers AM (1990) β-Agonistic properties of tulobuterol, a new β-sympathicomimetic drug, and its effects on pulmonary β-adrenoceptor characteristics. Lung 168 [Suppl]: 179–185

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Uematsu, T., Nakano, M., Kosuge, K. et al. The pharmacokinetics of the β2-adrenoceptor agonist, tulobuterol, given transdermally and by inhalation. Eur J Clin Pharmacol 44, 361–364 (1993). https://doi.org/10.1007/BF00316473

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00316473

Key words

  • Tulobuterol
  • β2-adrenoceptor agonist
  • aerosol inhalation
  • transdermal delivery
  • pharmacokinetics